TICKERNOMICS Sign up
Last Update: 2024-03-28 02:13:56
BioLineRx Ltd. ( BLRX ) https://www.biolinerx.com
1.03USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Israel
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
BLRX
19.77%
SPY
32.74%
-64.48%
BLRX
SPY
92.93%
-84.03%
BLRX
SPY
224.41%
-96.89%
BLRX
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
74.32
73.00
1.83
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.40
0.66
5.66
-59.26
0.00
-1.62
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.3872
-156.81
-95.20
1.64
Other Earnings and Cash Flow Stats:
BioLineRx Ltd. ( BLRX ) Net Income TTM ($MM) is -41.17
BioLineRx Ltd. ( BLRX ) Operating Income TTM ($MM) is -36.69
BioLineRx Ltd. ( BLRX ) Owners' Earnings Annual ($MM) is -33.62
BioLineRx Ltd. ( BLRX ) Current Price to Owners' Earnings ratio is -1.90
BioLineRx Ltd. ( BLRX ) EBITDA TTM ($MM) is -40.06
BioLineRx Ltd. ( BLRX ) EBITDA Margin is 0.00%
Capital Allocation:
BioLineRx Ltd. ( BLRX ) has paid 0.00 dividends per share and bought back -10.340109 million shares in the past 12 months
BioLineRx Ltd. ( BLRX ) has increased its debt by 2.624 million USD in the last 12 months
Capital Structure:
BioLineRx Ltd. ( BLRX ) Interest-bearing Debt ($MM) as of last quarter is 16
BioLineRx Ltd. ( BLRX ) Annual Working Capital Investments ($MM) are -2
BioLineRx Ltd. ( BLRX ) Book Value ($MM) as of last quarter is 13
BioLineRx Ltd. ( BLRX ) Debt/Capital as of last quarter is 128%
Other Balance Sheet Stats:
BioLineRx Ltd. ( BLRX ) has 7 million in cash on hand as of last quarter
BioLineRx Ltd. ( BLRX ) has 14 million of liabilities due within 12 months, and long term debt 11 as of last quarter
BioLineRx Ltd. ( BLRX ) has 61 common shares outstanding as of last quarter
BioLineRx Ltd. ( BLRX ) has 0 million USD of preferred stock value
Academic Scores:
BioLineRx Ltd. ( BLRX ) Altman Z-Score is -11.25 as of last quarter
BioLineRx Ltd. ( BLRX ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
BioLineRx Ltd. ( BLRX ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of BioLineRx Ltd. ( BLRX ) for the amount of $ on
9.46% of BioLineRx Ltd. ( BLRX ) is held by insiders, and 1.93% is held by institutions
BioLineRx Ltd. ( BLRX ) went public on 2011-07-25
Other BioLineRx Ltd. ( BLRX ) financial metrics:
FCF:-32.59
Unlevered Free Cash Flow:-36.40
EPS:-1.03
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-487.99
Beta:1.64
Buffet's Owners Earnings:-33.62
Price to Owner's Earnings:-1.90
About BioLineRx Ltd. ( BLRX ) :
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.